![](https://www.pymnts.com/wp-content/uploads/2023/05/Shutterstock_1883799319.jpg)
According to Reuters, two pharmaceutical companies were fined by China’s market regulator for engaging in monopolistic behavior.
Grand Pharmaceutical was fined 136 million yuan ($19.68 million) and had 149 million yuan of “illegal revenue” confiscated for engaging in a monopolistic agreement with Wuhan Healthcare Pharmaceuticals.
Related: UK: CMA accuses pharma firms of market allocation
Wuhan Healcare Pharmaceuticals was fined 4.13 million yuan by the regulator and had slightly over 30 million yuan of its revenue confiscated.
In recent months, Chinese regulatory authorities have initiated antitrust investigations on various sectors, with a particular focus on technology corporations, including Alibaba Group.
Featured News
Italy’s Competition Watchdog Probes Armani and Dior Over Worker Exploitation Claims
Jul 17, 2024 by
CPI
EU’s AI Legislation: Protection or Innovation Stifler?
Jul 17, 2024 by
CPI
House Oversight Panel to Probe Pharmacy Benefit Managers’ Role in Rising Healthcare Costs
Jul 16, 2024 by
CPI
Spanish Train Maker Talgo Receives Merger Offer from Czech Rival Skoda
Jul 16, 2024 by
CPI
Yandex Finalizes $5.4 B Asset Split, Marking Major Corporate Exit and Birth of New AI Venture
Jul 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI